We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA issued a warning letter to Indian drugmaker Wockhardt, citing violations of current good manufacturing practices (cGMPs) at its facility in Aurangabad, India.